Tiffany R. Stone

Tiffany R. Stone serves as a key procurement lead within the National Institute on Drug Abuse (NIDA), part of the National Institutes of Health under the Department of Health and Human Services. She manages acquisitions that support high-impact scientific research into substance use disorders, focusing on the procurement of specialized analytical laboratory instrumentation and related research support services. Her role is critical in translating NIDA’s mission into actionable contracting strategies that enable cutting-edge neurobiological and behavioral research. She routinely oversees complex, research-driven procurements requiring technical specificity, compliance with federal research funding guidelines, and alignment with NIH grantee priorities. Stone maintains longstanding relationships with leading academic medical institutions, including The McLean Hospital Corporation, the University of Maryland Baltimore, the University of Miami, the University of Pittsburgh, and the Icahn School of Medicine at Mount Sinai. These partnerships are primarily research collaboration and service-based contracts, often supporting clinical trials, neuroimaging studies, and laboratory analysis. Her contracting approach emphasizes long-term scientific continuity, with recurring engagements that foster institutional expertise and methodological consistency across multi-site research initiatives. She demonstrates a strong and consistent commitment to socioeconomic diversity in contracting, with 100% of her procurements designated as total small business set-asides under FAR 19.5. This reflects a deliberate strategy to prioritize small business participation, ensuring that innovative small firms with niche technical capabilities in analytical instrumentation and research support have equitable access to federal research funding streams. Her procurement activity is exclusively focused on NAICS 334516—Analytical Laboratory Instrument Manufacturing—indicating deep specialization in procuring advanced scientific equipment such as mass spectrometers, chromatography systems, and neurochemical analyzers. She works closely with vendors who provide calibrated, research-grade instrumentation and associated validation services essential for reproducible, high-fidelity data collection in addiction research laboratories.